Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.39 |
| ▸ | PDE5A | O76074 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | MIF | P14174 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11418285 | 0.81 | JAK2 (0.46) | JAK2JAK3CYP11B2PDE10AALDH1A1 | |
| SCHEMBL20653495 | 0.75 | JAK2 (0.39) | JAK2JAK3CYP11B2PDE10AKDM4E | |
| SCHEMBL798669 | 0.74 | AHR (0.33) | ALDH1A1KDM4ENPC1NAMPT | |
| SCHEMBL544142 | 0.74 | JAK2 (0.50) | JAK2JAK3CYP11B2PDE10AALDH1A1 | |
| SCHEMBL9108919 | 0.73 | PIK3CG (0.35) | ALDH1A1MEN1KMT2AKDM4ENPC1 | |
| SCHEMBL17131652 | 0.73 | JAK2 (0.58) | JAK2JAK3CYP11B2PDE10AALDH1A1 | |
| SCHEMBL9109466 | 0.73 | AHR (0.53) | NAMPT | |
| SCHEMBL18626423 | 0.73 | HAVCR2 (0.39) | PDE10APDE5AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL24983891 | 0.72 | JAK2 (0.36) | JAK2JAK3CYP11B2PDE10AKDM4E | |
| SCHEMBL12091357 | 0.72 | NAMPT (0.35) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230144095-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-05-11 | — | — | US | disclosed |
| US-9458179-B2 | Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-9394311-B2 | Triazolo compounds as PDE10 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150322089-A1 | QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150148332-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-8486967-B2 | Heteroaryl substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120225884-A1 | BRIDGED PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120028975-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND ANALOGS THEREOF | SCHERING CORPORATION | 2012-02-02 | — | — | US | disclosed |
| US-20120028975-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND ANALOGS THEREOF | SCHERING CORPORATION | 2012-02-02 | — | — | US | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | JAK2 3285/4885JAK3 2296/4885CYP11B2 4392/4885 |
| US-20230144095-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN1B, CACNA1A | JAK2 3336/4885JAK3 4239/4885CYP11B2 348/4885 |
| US-20120225884-A1 | BRIDGED PIPERIDINE DERIVATIVES | HPGDS, APP, PSEN1 | JAK2 3549/4885JAK3 4560/4885CYP11B2 2159/4885 |
| US-20150148332-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | PDE3A, PDE3B, PDE5A | JAK2 1030/4885JAK3 959/4885CYP11B2 152/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | JAK2 927/4885JAK3 2413/4885CYP11B2 4238/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | JAK2 3482/4885JAK3 3055/4885CYP11B2 2956/4885 |
| US-20120028975-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND ANALOGS THEREOF | PDE2A, PDE5A, PDE4A | JAK2 2127/4885JAK3 2062/4885CYP11B2 69/4885 |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | STING1, PDCD1LG2, CD274 | JAK2 1891/4885JAK3 2720/4885CYP11B2 4662/4885 |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | APP, HPGDS, PSEN1 | JAK2 3153/4885JAK3 4312/4885CYP11B2 2366/4885 |
| US-20150322089-A1 | QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA2, CHRNA1 | JAK2 4461/4885JAK3 3618/4885CYP11B2 2421/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | JAK2 582/4885JAK3 828/4885CYP11B2 3406/4885 |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, PPM1D | JAK2 2718/4885JAK3 3023/4885CYP11B2 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.